Phase 4 Eczema Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with atopic dermatitis (eczema) for at least 2 years, and this diagnosis has been confirmed at your screening visit using standard medical guidelines.
• Your eczema is moderate-to-severe, covering more than 10% of your body, and a doctor has rated it at least a 3 out of 4 in severity at both your screening and baseline visits.
• If you are a woman who could become pregnant, you must agree to use an approved form of contraception, or commit to not having sex, throughout the study and for 12 weeks after your last injection.
• You are willing and able to attend all required study visits and follow all study procedures.

Who may not be able to join:

• You weigh less than 30 kilograms (about 66 pounds).
• You have had an asthma attack serious enough to require a hospital stay in the past 12 months.
• Your asthma has not been well-controlled in the past 3 months (for example, symptoms more than twice a week, waking at night due to asthma twice or more per week, or asthma affecting your daily activities).
• You have a history of asthma and scored below 19 on a standard asthma control test (confirm with trial site).
• You have a current diagnosis of chronic obstructive pulmonary disease (COPD) or chronic bronchitis.
• You have had a skin infection in the week before your baseline visit, or any infection requiring prescription medication (antibiotics, antivirals, antifungals, or antiparasitic treatment) in the 2 weeks before your baseline visit.
• You have had a confirmed or suspected COVID-19 infection within 4 weeks before your screening or baseline visit.
• You received a COVID-19 vaccine within 4 weeks before your baseline visit.
• You have previously been treated with a medication called dupilumab (Dupixent).
• You are pregnant, breastfeeding, or planning to become pregnant during the study.
• You have a history of certain cancers in the past 5 years (some exceptions for specific treated skin cancers may apply — confirm with trial site).
• You have had a serious allergic reaction (including anaphylaxis) to a monoclonal antibody treatment or to lidocaine (a common local anaesthetic).
• You have a known active or latent (dormant) tuberculosis infection.
• You have a known or suspected weakened immune system, or a history of unusually frequent, severe, or long-lasting infections (confirm with trial site).
• You have, or have had, certain other skin conditions such as psoriasis, Netherton syndrome, cutaneous T-cell lymphoma, contact dermatitis, chronic actinic dermatitis, or dermatitis herpetiformis.
• You are expected to have major surgery during the study period.
• You are currently taking part in another clinical trial of a drug or medical device, or have done so in the past 8 weeks before screening.
• You have had a problem with alcohol or substance misuse in the past 6 months.
• You have a history of poor wound healing or keloid (raised scar) formation.

Important: Always verify eligibility with the trial site directly before applying.